Grataloup v. Monsanto and Novajardin

May 31, 2018
Not judged
France, Vienne, Isère

Sabine Grataloup, Thomas Grataloup
Monsanto, Novajardin
William Bourdon, Bertrand Repolt, Amélie Lefèvre

Civil court
Herbicide, Glyphosate, Roundup, Glyper
To have the recognition of the causal link between the child's deformities and exposure to glyphosate in utero, a pesticide used by the mother to treat her riding career.
High Court of Vienne, Isère, France

On May 31, 2018, Sabine Grataloup, mother of Théo Grataloup, then aged 11, assigned the American company Monsanto, and the French retailer Novajardin, before the Vienne First instance Tribunal. She blames Glypher, a glyphosate-based herbicide produced and marketed by Monsanto, for the congenital malformations her son has suffered since birth, namely severe malformations of the esophagus and larynx, preventing him from eating or expressing himself normally.

Sabine Grataloup was exposed to Glypher, then sold as a "biodegradable" product, when she weeded a horse-riding arena one month into her pregnancy, the stage at which the fetus's oesophagus and trachea develop.

In parallel with this procedure, which is still ongoing, Sabine Grataloup has also filed a claim for compensation with the Pesticide Victims Compensation Fund (Fonds d'Indemnisation des Victimes de Pesticides or FIVP). On March 10, 2022, FIVP experts officially recognized "the possibility of a causal link between the child's pathology and exposure to pesticides during the prenatal period due to the professional activity of one or both parents". As a result, Théo Grataloup will receive the sum of 36,000 euros, paid by the Agricultural Social Security, in compensation for the damage suffered.

This is the first time in France that the link between exposure to glyphosate during pregnancy and the development of congenital malformations in children has been recognized.